Literature DB >> 1870379

Effect of dapsone on haemoglobin concentration in patients with leprosy.

S R Byrd1, R H Gelber.   

Abstract

Haemolysis and frank anaemia from dapsone therapy of leprosy has been long recognized. However, the frequency and severity of this side-effect have not been well documented. We report herein a retrospective analysis of the effect of daily dapsone (generally 100 mg/day) on the haemoglobin concentration of 100 leprosy patients undergoing initial chemotherapy. The average haemoglobin was found to fall significantly by almost 2 g/dl, from 14.25 +/- 1.27 g/dl to a nadir of 12.31 +/- 1.61 (P less than 0.001). Eighty-three percent of patients had a fall of haemoglobin concentration of 1 g/dl or more, while in 16% of patients the haemoglobin fell greater than or equal to 3 g/dl. Increasing age was found associated with an increased magnitude of dapsone-related haemolysis (P less than or equal to 0.004). Decreasing the daily dose of dapsone was associated with an increased haemoglobin concentration (P less than 0.001%). We have concluded that dapsone commonly results in not only haemolysis but a significant decrease in haemoglobin concentration. This may have serious clinical implications, especially in endemic areas, where, owing to nutrition, malaria, and intestinal parasitism, the haemoglobin concentration is already compromised.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1870379     DOI: 10.5935/0305-7518.19910020

Source DB:  PubMed          Journal:  Lepr Rev        ISSN: 0305-7518            Impact factor:   0.537


  7 in total

Review 1.  Recognition and management of systemic lupus erythematosus.

Authors:  J O Schroeder; H H Euler
Journal:  Drugs       Date:  1997-09       Impact factor: 9.546

2.  Use of Dapsone in the Treatment of Chronic Idiopathic and Autoimmune Urticaria.

Authors:  Sydney E Liang; Rachel Hoffmann; Erik Peterson; Nicholas A Soter
Journal:  JAMA Dermatol       Date:  2019-01-01       Impact factor: 10.282

3.  Dapsone hydroxylamine induces premature removal of human erythrocytes by membrane reorganization and antibody binding.

Authors:  Luciana Bordin; Cristina Fiore; Francesco Zen; Michael D Coleman; Eugenio Ragazzi; Giulio Clari
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

Review 4.  A comprehensive insight into the anti-inflammatory properties of dapsone.

Authors:  Mina Khalilzadeh; Maryam Shayan; Sina Jourian; Mohammad Rahimi; Mohammad Sheibani; Ahmad Reza Dehpour
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2022-09-20       Impact factor: 3.195

5.  Double-blind placebo-controlled trial of dapsone in antihistamine refractory chronic idiopathic urticaria.

Authors:  Matt Morgan; Andrew Cooke; Laura Rogers; Beverley Adams-Huet; David A Khan
Journal:  J Allergy Clin Immunol Pract       Date:  2014 Sep-Oct

Review 6.  Chronic Urticaria: Advances in Understanding of the Disease and Clinical Management.

Authors:  Liting He; Wanyu Yi; Xin Huang; Hai Long; Qianjin Lu
Journal:  Clin Rev Allergy Immunol       Date:  2021-09-16       Impact factor: 8.667

7.  Treatment of refractory IgA vasculitis with dapsone: a systematic review.

Authors:  Keum Hwa Lee; Sung Hwi Hong; Jinhae Jun; Youngheun Jo; Woogyeong Jo; Dayeon Choi; Jeongho Joo; Guhyun Jung; Sunghee Ahn; Andreas Kronbichler; Michael Eisenhut; Jae Il Shin
Journal:  Clin Exp Pediatr       Date:  2019-09-24
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.